Effect of Allopurinol administration on the uric acid level and kidney function in paediatrics with tumour lysis syndrome (TLS) and high-risk TLS
DOI:
https://doi.org/10.46542/pe.2023.234.8791Keywords:
Allopurinol, Creatinine serum, Paediatric, Tumour lysis syndrome, Uric acidAbstract
Background: Tumor lysis syndrome (TLS) is a life-threatening oncologic emergency because of the release of tumour cell components such as uric acid, which can lead to hyperuricemia and acute kidney injury (AKI).
Objective: To analyse serum uric acid, creatinine, and BUN levels pre- and post-allopurinol administration.
Method: This study was a prospective observational study conducted from March to July 2020. Inclusion criteria were haematological malignancies in paediatric patients with TLS and high-risk TLS who received allopurinol 10 mg/kg/day in 2-3 divided doses. Collected data were the serum uric acid, creatinine, and BUN levels pre- and post-allopurinol administration.
Result: There were 14 sample in total during the study. There was a significant difference in uric acid level on day six after allopurinol administration compared to baseline in patients with high-risk TLS (p < 0.05).
Conclusion: Allopurinol was inadequate in reducing uric acid levels in TLS patients but adequate in reducing uric acid levels in patients with high-risk TLS.
References
Arozal, W., Watanabe, K., Veeraveedu, P., Ma, M., Thandavarayan, R.A., Sukumaran, V., Suzuki, K., Kodama, M., & Aizawa, Y. (2010). Protective effect of carvedilol on daunorubicin-induced cardiotoxicity and nephrotoxicity in rats. Toxicology, 274(1-3), 18-26. https://doi.org/10.1016/j.tox.2010.05.003
Aslan, G., Afsar, B., & Sag, A. (2019). The Effect of urine pH and urinary uric acid levels on the development of contrast nephropathy. Kidney and Blood Pressure Research. 45(1), 131‒141. https:// doi.org/10.1159/000504547
Benn, C.L., Dua, P., Gurrell, R., Loudon, P., Pike, A., Storer, R.I., & Vangjeli, C. (2018). Physiology of hyperuricemia and urate-lowering treatments. Frontiers in Medicine, 5,160. https://doi.org/10.3389/fmed.2018.00160
Bewersdorf, J.P., & Zeidan, A. (2020). Hyperleukocytosis and leukostasis in acute myeloid leukemia: Can a better understanding of the underlying molecular pathophysiology lead to novel treatments? MDPI, 9(10), 1-20. https://doi.org/10.3390/cells9102310
Burns, R.A., Topoz, I., & Reynolds, S.L. (2014). Tumor lysis syndrome: Risk factors, diagnosis, and management. Pediatric Emergency Care. 30(8), 571–576. https:// doi.org/10.1097/PEC.0000000000000195
Den Bakker, E., Gemke, R.J., & Bökenkamp, A. (2018). Endogenous markers for kidney function in children: A review. Critical Reviews in Clinical Laboratory Sciences, 55(3), 163-183. https://doi.org/10.1080/10408363.2018.1427041
Edeani, A., & Shirali, A. (2016). Tumor lysis syndrome. American Society of Nephrology, 1-8
Gupta, S., Gudsoorkar, P., & Jhaveri, K. (2022). Acute kidney injury in critically Ill patients with cancer. Clinical Journal of the American Society of Nephrology, 17(8), 1–14. https://doi.org/10.2215/CJN.15681221
Hoff, L.S., Goldenstein-Schainberg, C., & Fuller, R. (2020). Nephrolithiasis in gout: Prevalence and characteristics of brazilian patients. Advances in Rheumatology, 60. https://doi.org/10.1186/s42358-019-0106-4
Jones, G.L., Will, A., Jackson, G.H., Webb, N.J., Rule, S., & British Committee for Standards in Haematology. (2015). Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British committee for standards in haematology. British Journal of Haematology, 169(5), 661–671. https://doi.org/10.1111/bjh.13403
Lameire, N. (2014). Nephrotoxicity of recent anti-cancer agents. Clinical Kidney Journal, 7(1), 11–22. https://doi.org/10.1093/ckj/sft135
Li, H.C.W., Chung, O.K.J., Tam, C.J., & Chiu, S.Y. (2015). Effective prevention and management of tumor lysis syndrome in children with cancer: The important contributions of pediatric oncology nurses. Journal of Pediatric Oncology Nursing, 32(4), 209-218. https://doi.org/10.1177/1043454214555551
McDonagh, E.M., Thorn, C.F., Callaghan, J.T., Altman, R.B., & Klein, T.E. (2014). Pharmgkb summary: Uric acid-lowering drugs pathway, pharmacodynamics. Pharmacogenetics and genomics, 24(9), 464. https://doi.org/10.1097/FPC.0000000000000058
Renyi, I., Bardi, E., Udvardi, E., Kovacs, G., Bartyik, K., Kajtar, P., Masat, P., Nagy, K., Galantai, I., & Kiss, C. (2007). Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-hodgkin’s lymphoma. Pathology and Oncology Research, 13(1), 57-62. https://doi.org/10.1007/BF02893442
Sevinier, B., Demirkaya, M., Baytan, B., & Gunes, A.M. (2011). Hyperuricemia and tumor lysis syndrome in children with non-hodgkin's lymphoma and acute lymphoblastic leukemia. Turkish Journal of Hematology, 28(1). https://10.5152/tjh.2011.06
Sury, K. (2019). Update on the prevention and treatment of tumor lysis syndrome. Journal of Onco-Nephrology, 3(1), 19–30. https://doi.org/10.1177/2399369319837212
Tazi, I., Nafil, H., Elhoudzi, J., Mahmal, L., & Harif, M. (2011). Management of pediatric tumor lysis syndrome. Arab Journal of Nephrology and Transplantation, 4(3), 147–154. https:// 10.4314/ajnt.v4i3.71027
Villas, J.M.C. (2019). Tumour lysis syndrome. Medicina Clinica. 152(10), 397-404. https://doi.org/10.1016/j.medcle.2019.03.006
Williams, S.M., & Killeen, A.A. (2019). Tumor lysis syndrome. Archives of Pathology and Laboratory Medicine, 143(3), 386-393. https:// doi.org/10.5858/arpa.2017-0278-RS
Wilson, F.P., & Berns, J.S. (2012). Onco-nephrology: Tumor lysis syndrome. Clinical Journal of the American Society of Nephrology, 7(10), 1730-1739. https://doi.org/10.2215/CJN.03150312
